Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 9498536
APP PUB NO 20140294931A1
SERIAL NO

14242041

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

Thyroid hormone antagonists and their nanoparticle formulations (Nanotetrac™ or Nanotriac™) act at a cell surface receptor to block angiogenesis and tumor cell proliferation. The complex anti-angiogenic performs actions on specific cytokines and chemokines. Thyroid hormone antagonists inhibit expression in tumor cells of cytokine genes, e.g., specific interleukins, and chemokine genes, such as fractalkine (CX3CL1), and chemokine receptor genes (CX3CR1) that are targets in the development of inflammation-suppressant drugs. This application discloses a novel composition of Tetra or Tri-iodothyroacetic acid (tetrac or triac), other thyroid partial agonists or antagonists and their nanoparticle formulations conjugated to polymers and encapsulating non-steroidal anti-inflammatory, anti-inflammatory glucocorticoids, and/or polyphenols for the management of various acute and chronic inflammatory disorders ranging from neurological, vascular, and musculoskeletal disorders.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
NANOPHARMACEUTICALS LLCBRANFORD, CT16

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Davis, Paul J West Sand Lake, US 45 655
Mousa, Shaker A Wynantskill, US 58 347

Cited Art Landscape

Patent Info (Count) # Cites Year
 
Other [Check patent profile for assignment information] (2)
2004/0013,728 Controlled drug delivery system using the conjugation of drug to biodegradable polyester 11 2003
2005/0272,817 Dermatological use and a dermatological preparation 11 2005
 
Emisphere Technologies, Inc. (1)
4925673 Delivery systems for pharmacological agents encapsulated with proteinoids 356 1987
 
BBB Holding B.V. (1)
8026209 Methods and compositions for targeting agents into and across the blood-barrier and other endothelial cell microvascular barriers 17 2004
 
NEKTAR THERAPEUTICS (2)
6515100 Soluble, degradable poly (ethylene glycol) derivatives for controllable release of bound molecules into solution 114 2001
2001/0021,763 Soluble, degradable poly (ethylene glycol) derivatives for controllable release of bound molecules into solution 62 2001
 
La Jolla Cancer Research Foundation (1)
4789734 Vitronectin specific cell receptor derived from mammalian mesenchymal tissue 150 1985
 
Northern Therapeutics Inc. (1)
6482406 Cell-based gene therapy for the pulmonary system 22 1999
 
LIGHT SCIENCES CORPORATION (1)
2002/0049,247 Novel treatment for eye disease 43 2001
 
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (1)
5410016 Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers 584 1993
 
MITSUBISHI PHARMA CORPORATION (1)
2003/0165,576 Antitumor effect potentiators 56 2003
 
Technicon Instruments Corporation (1)
4650751 Protected binding assay avoiding non-specific protein interference 20 1983
 
NANOPHARMACEUTICALS LLC (20)
* 7785632 Thyroid hormone analogs and methods of use 10 2004
* 2005/0124,862 Thyroid hormone analogs and methods of use 12 2004
8071134 Thyroid hormone analogs and methods of use 12 2005
* 2008/0124,280 Thyroid Hormone Analogs and Methods of Use 11 2005
* 8668926 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof 46 2007
2010/0112,079 Thyroid Hormone Analogs and Methods of Use 9 2009
* 2010/0159,021 Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of Use 10 2009
* 9180107 Combination treatment of cancer with cetuximab and tetrac 3 2010
2010/0255,108 Combination Treatment of Cancer With Cetuximab and Tetrac 9 2010
* 9220788 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof 3 2010
* 2011/0052,715 NANOPARTICLE AND POLYMER FORMULATIONS FOR THYROID HORMONE ANALOGS, ANTAGONISTS, AND FORMULATIONS AND USES THEREOF 11 2010
9289395 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof 3 2010
* 2011/0142,941 Nanoparticle and Polymer Formulations for Thyroid Hormone Analogs, Antagonists, and Formulations and Uses Thereof 12 2010
9272049 Methods of stimulating fat mobilization using a polymer conjugated polyphenol 3 2011
2012/0258,069 RGD-BINDING COMPOUNDS AND METHODS OF USE 8 2011
* 8802240 Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells 8 2012
2012/0315,320 USES OF FORMULATIONS OF THYROID HORMONE ANALOGS AND NANOPARTICULATE FORMS THEREOF TO INCREASE CHEMOSENSIVITY AND RADIOSENSITIVITY IN TUMOR OR CANCER CELLS 9 2012
2014/0072,646 THYROID HORMONE ANALOGS AND METHODS OF USE 9 2013
* 9198887 Thyroid hormone analogs and methods of use 3 2013
2014/0072,635 THYROID HORMONE ANALOGS AND METHODS OF USE 8 2013
 
ARCH DEVELOPMENT CORPORATION (1)
5438126 Human thyroid hormone receptor DNA 21 1992
 
RENEURON, INC. (1)
5648506 Water-soluble polymeric carriers for drug delivery 146 1995
 
Medipro Sciences Limited (1)
5482719 Drug delivery systems 70 1992
 
ARIZEKE PHARMACEUTICALS, INC. (1)
2005/0249,721 Compositions and methods for targeted biological delivery of molecular carriers 18 2005
 
CLINICAL DIAGNOSTIC SYSTEMS INC. (1)
4801504 Fluorescent labels having a polysaccharide bound to polymeric particles 34 1987
 
Tracie Martyn International, LLC (1)
* 2006/0216,251 Topical formulations and methods of use 34 2006
 
CREATIVE BIOMOLECULES, INC. (1)
5091513 Biosynthetic antibody binding sites 333 1991
 
SANGAMO BIOSCIENCES, INC. (2)
7358085 Anti-angiogenic methods and compositions 5 2006
2006/0210,539 Anti-angiogenic methods and compositions 15 2006
 
OHR PHARMACEUTICAL, INC. (1)
2001/0046,521 Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities 13 2001
 
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (3)
4801575 Chimeric peptides for neuropeptide delivery through the blood-brain barrier 199 1986
6818620 Synthetic compounds and compositions with enhanced cell binding 22 2001
2003/0162,758 Treatment for age-related macular degeneration (AMD) 19 2002
 
SANGSTAT MEDICAL CORPORATION (1)
6013641 Use of hyaluronic acid as an immunosuppressant 16 1996
 
Becton Pharma, Inc. (1)
6740680 Pharmaceutical compositions to tetrac and methods of use thereof 17 2002
 
THE UNIVERSITY OF BRITISH COLUMBIA (1)
2002/0137,676 Selective treatment of endothelial somatostatin receptors 16 2001
 
CORNELL UNIVERSITY (1)
2003/0027,940 Biodegradable copolymers linked to segment with a plurality of functional groups 10 2002
 
OSMOTICA KERESKEDELMI ES SZOLGALTATO KFT (1)
* 2002/0132,005 Combined diffusion / osmotic pumping drug delivery system 11 2002
 
UNIVERSITY OF CINCINNATI (1)
* 2001/0023,254 Use of sulfamate derivatives for treating impulse control disorders 6 2000
 
DEUTSCHES KREBSFORSCHUNGSZENTRUM (1)
2005/0222,387 Smac-peptides as therapeutics against cancer and autoimmune diseases 12 2005
 
BIOGEN IDEC MA INC. (1)
2009/0175,862 COMBINATION THERAPY EMPLOYING LYMPHOTOXIN BETA RECEPTOR BINDING MOLECULES IN COMBINATION WITH SECOND AGENTS 10 2008
 
AVENTIS PHARMA S.A. (2)
5766635 Process for preparing nanoparticles 102 1995
6139870 Stabilized nanoparticles which are filterable under sterile conditions 91 1998
 
ORDWAY RESEARCH INSTITUTE, INC. (1)
2010/0209,382 Polyphenol Conjugates as RGD-Binding Compounds and Methods of Use 11 2006
 
RESVERATROL PARTNERS, LLC (1)
2005/0158,376 Dietary supplement and method of processing same 30 2004
 
STRYKER CORPORATION (1)
4968590 Osteogenic proteins and polypeptides 173 1988
 
KNOLL BV (1)
5225204 Stable dosage of levothyroxine sodium and process of production 56 1991
 
Orway Research Institute, Inc. (1)
8518451 Thyroid hormone analogs and methods of use 9 2009
 
Unisearch Associates Inc. (1)
2003/0138,557 Composition and method for the encapsulation of water-soluble molecules into nanoparticles 31 2002
 
The Scripps Research Institute (1)
6316412 Polypeptides for promoting cell attachment 20 1998
 
MASSACHUSETTS INSTITUTE OF TECHNOLOGY (2)
4906474 Bioerodible polyanhydrides for controlled drug delivery 187 1984
* 2008/0081,074 Polymers for functional particles 83 2007
 
THOMAS JEFFERSON UNIVERSITY (1)
6821947 Endorepellin: methods and compositions for inhibiting angiogenesis 11 2001
 
Angstrom Pharmaceuticals, Inc. (1)
7807621 Anti-invasive and anti-angiogenic compositions 13 2006
 
UNIVERSITY OF ROCHESTER (1)
5231000 Antibodies to A4 amyloid peptide 139 1991
 
Mylan Pharmaceuticals, Inc. (2)
6936274 Storage stable thyroxine active drug formulations and methods for their production 7 2003
2004/0033,259 Storage stable thyroxine active drug formulations and methods for their production 11 2003
 
INTEZYNE TECHNOLOGIES, INC. (1)
7638558 Polymeric micelles for drug delivery 39 2006
 
M. Alphabet 1, LLC (1)
2014/0199,375 COMBINATION THERAPY FOR SKIN DISORDERS 6 2014
 
INTERMUNE, INC. (1)
* 2007/0117,841 Use of pirfenidone in therapeutic regimens 21 2004
 
Southern Arizona Veterans Affairs Health Care System (2)
6534676 Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same 6 2001
2002/0151,594 Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same 11 2001
 
THE REGENTS OF THE UNIVERSITY OF MICHIGAN (1)
5571840 Method for treating central nervous system ischemia 25 1994
 
BROWN UNIVERSITY (1)
5011486 Composite nerve guidance channels 49 1988
 
ROCHE DIAGNOSTICS OPERATIONS, INC. (1)
* 2006/0166,303 Use of cardiac hormones for assessing a cardiovascular risk with respect to the administration of anti-inflammatory drugs 8 2005
 
DENDREON PHARMACEUTICALS LLC (1)
6677473 Plasminogen activator inhibitor antagonists 50 2000
 
THE GENERAL HOSPITAL CORPORATION (1)
5733871 Methods for the treatment of neuronal damage associated with ischemia, hypoxia or neurodegeneration 13 1995
 
ADVANCED NUCLIDE TECHNOLOGIES, LLC (1)
2008/0193,377 Radiolabeled Nanohybrids Targeting Solid Tumor Neovasculature and Method of Using Same 16 2005
 
PHARMASCIENCE, INC. (1)
6414037 Pharmaceutical formulations of resveratrol and methods of use thereof 59 1999
 
TECHNION RESEARCH & DEVELOPMENT FOUNDATION LTD. (1)
5591709 Compositions and methods for treating wounds 70 1995
 
Item Development AB (1)
5449665 Continuous intravenous infusion of adenosine to human patients undergoing percutaneous transluminal angioplasty 20 1993
 
NEXSTAR PHARMACEUTICALS, INC. (1)
5593688 Liposomal targeting of ischemic tissue 27 1995
 
Hitachi Tools Engineering Ltd. (1)
7166155 Hard film and hard film-coated tool 27 2003
 
BTG INTERNATIONAL INC. (1)
5158978 Thyroid hormone treatment of acute cardiovascular compromise 30 1991
 
ALBANY COLLEGE OF PHARMACY (1)
* 2009/0022,806 Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof 26 2007
 
CHILDREN'S HOSPITAL LOS ANGELES (1)
2003/0157,098 Methods for inhibiting brain tumor growth 13 2003
 
UNIVERSITY OF SOUTH FLORIDA (1)
2007/0190,160 Nanoparticles for drug-delivery 34 2004
 
BOSTON SCIENTIFIC SCIMED, INC. (1)
5304121 Drug delivery system making use of a hydrogel polymer coating 734 1991
 
MERCK PATENT GMBH (1)
* 2008/0199,850 Egfr Dependent Modulation of Chemokine Expression and Influence on Therapy and Diagnosis of Tumors and Side Effects Thereof 3 2006
 
BOEHRINGER MANNHEIM ITALIA S.P.A. (1)
5104895 Platinum(II) complexes, their preparation and use as anti-tumor agents 18 1990
 
PRESIDENT AND FELLOWS OF HARVARD COLLEGE (2)
2005/0171,027 Compositions for treating or preventing obesity and insulin resistance disorders 40 2004
8242171 Method for reducing the weight of a subject or inhibiting weight gain in a subject 13 2010
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

  • No Forward Cites to Display

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 May 22, 2020
7.5 Year Payment $3600.00 $1800.00 $900.00 May 22, 2024
11.5 Year Payment $7400.00 $3700.00 $1850.00 May 22, 2028
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00